All In Biotech

Drug Trial Radar · NCT06538207

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Jan 13, 2021

Primary completion

Oct 1, 2024

Study completion Jan 30, 2025

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic cancer.

Conditions

  • Metastatic Pancreatic Cancer

Interventions

  • ONO-4578Drug

    Specified dose on specified days

  • ONO-4538Drug

    Specified dose on specified days

  • OxaliplatinDrug

    Specified dose on specified days

  • LevofolinateDrug

    Specified dose on specified days

  • IrinotecanDrug

    Specified dose on specified days

  • FluorouracilDrug

    Specified dose on specified days

  • GemcitabineDrug

    Specified dose on specified days

  • Nab-PaclitaxelDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities(DLT)Time frame: 28 days
  2. Adverse event(AE)Time frame: UP to 28 days after the last dose

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Hospital East

    Kashiwa-shi, Chiba, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, Japan

  • Seirei Hamamatsu General Hospital

    Hamamatsu, Shizuoka, Japan

  • Juntendo University Hospital

    Bunkyō-Ku, Tokyo, Japan

  • The University of Tokyo Hospital

    Bunkyō-Ku, Tokyo, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • The Cancer Institute Hospital of JFCR

    Koto-Ku, Tokyo, Japan

  • Kyorin University Hospital

    Mitaka-shi, Tokyo, Japan

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.